Assay for ADAMTS-13 Activity with Flow Cytometric Readout.

Area of Science:

• Biochemistry
• Hematology
• Analytical Chemistry

Background:

• ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a metalloprotease regulating von Willebrand factor (vWF) multimer size.
• Severe deficiency in ADAMTS-13 activity (<10%) causes thrombotic thrombocytopenic purpura (TTP), a critical thrombotic microangiopathy (TMA).
• Accurate ADAMTS-13 activity measurement is vital for differentiating TTP from other TMAs and guiding treatment decisions.

Purpose of the Study:

• To develop and validate a novel vWF/mAb-based assay for quantifying plasma ADAMTS-13 activity using flow cytometry.
• To expand the analytical platforms available for ADAMTS-13 activity determination.
• To provide a reliable method for discriminating TTP from other TMAs.

Main Methods:

• Development of a specific vWF/monoclonal antibody (mAb)-based assay.
• Utilizing flow cytometry for quantitative readout of ADAMTS-13 activity.
• Validation of the assay using patient plasma samples and comparison with a commercial ELISA.

Main Results:

• The assay demonstrated a total time of 80-90 minutes.
• A near-linear dynamic range from 0.005 to 0.2 IU/mL was observed.
• Excellent agreement with the clinical 0.1 IU/mL TTP threshold was found when analyzing patient samples.

Conclusions:

• The developed flow cytometry assay is a reliable method for determining plasma ADAMTS-13 activity.
• This assay can be readily implemented in laboratories equipped with flow cytometers.
• The assay facilitates accurate diagnosis and management of TTP.